Therapy News and Research

RSS

Geriatric chronic kidney disease patients benefit from SGLT2 inhibition

New research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2026 October 22–25.

26 Oct 2026

Next generation KRAS inhibitor divarasib significantly extends lung cancer survival

Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS targeted therapy divarasib, according to researchers from The University of Texas MD Anderson Cancer Center.

26 Oct 2026

Personalized mRNA cancer vaccine cuts melanoma recurrence risk when added to immunotherapy

Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026.

24 Oct 2026

Abiraterone triplet therapy improves long-term survival in metastatic prostate cancer

Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification.

24 Oct 2026

Drug combination delivers promising survival gains in advanced endometrial cancer

An immunotherapy-based regimen combining durvalumab and the PARP inhibitor, olaparib, demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson Cancer Center.

24 Oct 2026

Kidney Week 2026 features late-breaking clinical trials in kidney care

The American Society of Nephrology, has selected the following late breaking clinical trials to be presented in-person at Kidney Week 2026 October 22–25.

24 Oct 2026

Nearly one third of patients with advanced melanoma saw tumors disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy

Results from a clinical trial have revealed nearly one third (29.2 percent) of patients with advanced melanoma saw their tumors disappear completely on scans after receiving lifileucel TIL therapy alongside an immune checkpoint inhibitor, pembrolizumab, as a first-line treatment.

24 Oct 2026

LGBTQ+ college students facing discrimination report higher mental health risks

LGBTQ+ college students who experience discrimination are significantly more likely to experience depression, anxiety, suicidal thoughts, and avoid needed health care, according to a new national study by Columbia University Mailman School of Public Health, Boston University School of Public Health and Harvard Pilgrim Health Care Institute.

23 Oct 2026

New guidance expands reproductive care for people with cystic fibrosis

For much of the history of cystic fibrosis (CF) care, reproductive health was not a major part of the conversation. Fertility challenges were the norm for men and women with this genetic disorder, and many grew up assuming biological parenthood was not possible.

23 Oct 2026

Novel immunosuppressant improves kidney function and quality of life after transplantation

The Phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults receiving their first kidney transplant.

23 Oct 2026

Common kidney tests underestimate chronic kidney disease in cancer patients

New research indicates that commonly used measures of kidney function largely underestimate the prevalence of chronic kidney disease (CKD) in patients with cancer. The findings will be presented at ASN Kidney Week 2026 October 22–25.

23 Oct 2026

KRAS-targeting vaccine prompts immune responses in pancreatic cancer patients

An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers.

23 Oct 2026

Targeted drug extends survival across diverse pancreatic cancer patient groups

A new analysis of a phase 3 clinical trial found that the targeted drug daraxonrasib improved survival compared with standard chemotherapy across multiple groups of patients with advanced pancreatic cancer, including those with different RAS mutations and those without an identified RAS mutation.

23 Oct 2026

Researchers identify molecular target to improve pancreatic cancer treatment

Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers. One reason for its resistance to therapy is the dense tissue surrounding the tumor, which acts as a protective barrier and suppresses the immune response.

23 Oct 2026

Maternal stress alters placental pathways affecting fetal brain development

About one in five U.S. women experience maternal mental health conditions, and chronic stress during pregnancy can contribute to risk for both maternal and child health challenges.

23 Oct 2026

Study identifies potential new ways to treat the most common type of bowel cancer

Major new research published today identifies potential new ways to treat the most common type of bowel cancer in Ireland.

23 Oct 2026

Decipher tissue-based molecular test helps personalize high-risk prostate cancer treatment

Prostate cancer is the most common cancer in men – in 2013, it affected more than one million men across the world.

23 Oct 2026

Medicare is more broken than we thought

By Oct. 1, at least 2 million seniors will have received alarming notices: Their health plans — which they get through Medicare Advantage, the version of Medicare run by private health insurance companies — will disappear at the end of the year.

23 Oct 2026

What can 6,000 brain scans tell us about Alzheimer's?

KARI's multimodal imaging dataset reveals critical insights into Alzheimer's disease, linking amyloid, tau, and brain structure to cognitive performance.

23 Oct 2026

Dual-targeted therapy shows promise against metastatic triple-negative breast cancer

A new preclinical study suggests that attacking triple-negative breast cancer (TNBC) in two ways at once can kill cancer cells, slow tumor growth and limit the cancer's spread. Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) developed the approach.

23 Oct 2026

Previous
1
...
3
4
5
6
7
8
9
...
2953
Next

Therapy News and Research

Geriatric chronic kidney disease patients benefit from SGLT2 inhibition

Next generation KRAS inhibitor divarasib significantly extends lung cancer survival

Personalized mRNA cancer vaccine cuts melanoma recurrence risk when added to immunotherapy

Abiraterone triplet therapy improves long-term survival in metastatic prostate cancer

Drug combination delivers promising survival gains in advanced endometrial cancer

Kidney Week 2026 features late-breaking clinical trials in kidney care

Nearly one third of patients with advanced melanoma saw tumors disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy

LGBTQ+ college students facing discrimination report higher mental health risks

New guidance expands reproductive care for people with cystic fibrosis

Novel immunosuppressant improves kidney function and quality of life after transplantation

Common kidney tests underestimate chronic kidney disease in cancer patients

KRAS-targeting vaccine prompts immune responses in pancreatic cancer patients

Targeted drug extends survival across diverse pancreatic cancer patient groups

Researchers identify molecular target to improve pancreatic cancer treatment

Maternal stress alters placental pathways affecting fetal brain development

Study identifies potential new ways to treat the most common type of bowel cancer

Decipher tissue-based molecular test helps personalize high-risk prostate cancer treatment

Medicare is more broken than we thought

What can 6,000 brain scans tell us about Alzheimer's?

Dual-targeted therapy shows promise against metastatic triple-negative breast cancer

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News